Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

immunization

- PMLiVE

Impetus Digital: now offering carbon-neutral live meeting support

Impetus Digital was promoted to the Aclymate Silver Tier for their efforts in crafting carbon-neutral virtual and live meetings for life science companies.

Impetus Digital

- PMLiVE

Novartis’ Kisqali recommended by NICE to treat broad early breast cancer population

The drug was previously available only for patients whose cancer had spread to nearby lymph nodes

- PMLiVE

MHRA approves KalVista Pharmaceuticals’ Ekterly to treat hereditary angioedema attacks

Ekterly is now the first and only oral on-demand treatment for HAE to be approved by the UK regulator

- PMLiVE

GCI Health announces realignment of European leadership team

The new structure will see Annalise Coady step into the role of president, Europe

- PMLiVE

Uniphar Rebrands On Demand Business to Uniphar Global Sourcing, Strengthening Global Pharmaceutical Offering

Dublin, Ireland 16th July 2025 – Leading global healthcare services provider, Uniphar, has launched Uniphar | Global Sourcing, a new identity for its On Demand business that strengthens its position...

Uniphar

Bayer symbol

Bayer’s Kerendia granted FDA approval for new heart failure indication

Approximately 55% of the 6.7 million adults in the US with HF have an LVEF of at least 40%

EU flag

EC approves BeOne Medicines’ Tevimbra to treat nasopharyngeal cancer

The form of head and neck cancer accounted for around 133,000 new global cancer cases in 2020

- PMLiVE

Pfizer/Astellas share positive overall survival results for Xtandi in prostate cancer

Around 55,100 cases of prostate cancer are diagnosed in the UK every year

- PMLiVE

NEW SENIOR ROLES AS FOUR TAKES NEXT STEP IN SECTOR & SERVICE STRATEGY

Kelly Smith and Sam Khachikyan to lead £32m turnover media service Mohaned Lafi to spearhead Middle East growth as chief executive MENA Louay Houri takes on new global role as...

Four Agency Worldwide

- PMLiVE

AbbVie gains rights to IGI’s phase 1 trispecific engager in deal worth over $1.9bn

ISB 2001 is in early-stage clinical development for relapsed/refractory multiple myeloma

- PMLiVE

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE

The rare inherited disease affects approximately 11,000 people in the UK

- PMLiVE

AstraZeneca’s baxdrostat shows promise in phase 3 hypertension study

Around 1.3 billion people globally are living with consistently high blood pressure levels

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links